Apple Cinnamon Overnight Oats with Chia Seeds
October 22, 2026
No Comments
GLP-1 medicines have changed the conversation around obesity and weight management.
For many people, medicines such as semaglutide, liraglutide and the dual GIP/GLP-1 agonist tirzepatide can substantially reduce appetite and food intake while producing clinically meaningful weight loss.[1–4]
But their success has also created a new nutrition problem.
When hunger falls dramatically, eating less becomes relatively easy. Eating well enough can become surprisingly difficult.
A person may feel full after half a meal. Foods they previously enjoyed may suddenly seem unappealing. Nausea, constipation, reflux or diarrhoea may interfere with eating. Meals may be skipped because there is simply little interest in food.
The number on the scale may be moving in the desired direction while protein, fibre, fluid, vitamins, minerals—and potentially lean tissue—receive far less attention.
That distinction matters.
In 2025, the World Health Organization placed GLP-1 therapies within a broader model of comprehensive obesity care rather than presenting medication as a stand-alone solution. WHO describes obesity as a chronic, relapsing disease requiring comprehensive and potentially lifelong care, with healthy dietary patterns, physical activity and professional support remaining important components of treatment.[1]
This changes the nutrition question.
The question is no longer:
“How little can I eat while taking a GLP-1?”
A much better question is:
“How can I make a smaller appetite nutritionally sufficient?”
That is where clinical nutrition becomes essential.
GLP-1, or glucagon-like peptide-1, is a hormone involved in appetite regulation, glucose control and gastrointestinal function.
Medicines acting on the GLP-1 pathway can increase feelings of fullness, reduce hunger and food intake, influence insulin and glucagon responses, and slow gastric emptying to varying degrees.[1,5]
Tirzepatide additionally acts on the glucose-dependent insulinotropic polypeptide, or GIP, receptor.[4]
These effects help explain why someone who previously struggled with persistent hunger may suddenly find that a relatively small meal is enough.
That can be therapeutically valuable.
But appetite suppression does not selectively remove foods we do not need.
A lower appetite can mean less dessert and fewer energy-dense snacks—but it can also mean less protein, less calcium, fewer vegetables, insufficient fibre and inadequate fluid.
Therefore, reduced food quantity increases the importance of food quality.
The smaller the nutritional window becomes, the more carefully it needs to be used.
One of the most important concepts for anyone using GLP-1 therapy is that body weight and body fat are not interchangeable.
When body weight decreases substantially, the lost tissue generally includes both fat mass and lean mass.
Lean mass is not synonymous with skeletal muscle—it also includes water, organs and other non-fat tissues—but skeletal muscle is an important component.
Body-composition analyses from major GLP-1–based obesity trials show substantial reductions in fat mass alongside reductions in lean mass.[6,7]
This should not be interpreted to mean that GLP-1 medicines uniquely “destroy muscle.” Loss of lean tissue can occur during substantial weight reduction through many approaches, including energy-restricted diets and bariatric surgery.
But it does mean that muscle preservation deserves deliberate attention during treatment, particularly when weight is being lost rapidly or food intake becomes very low.
This is especially relevant for people who begin treatment with low muscle mass, older adults, people with repeated histories of restrictive dieting, sedentary individuals and women approaching or beyond menopause.
The goal of treatment should therefore not be:
Maximum weight loss at any nutritional cost.
It should be improvement in health while preserving as much physical function, nutritional status and metabolically valuable tissue as possible.
When appetite falls, protein is often one of the first nutritional priorities to assess.
Protein supports skeletal muscle, enzymes, immune function and numerous other physiological processes. During active weight loss, sufficient protein becomes particularly relevant because energy restriction itself creates pressure toward loss of lean tissue.[8]
The standard adult Recommended Dietary Allowance of approximately 0.8 g/kg/day is designed as a population reference for meeting basic protein requirements. It should not automatically be interpreted as the optimal target for every person undergoing substantial intentional weight loss.[8]
Higher protein intakes have consequently been proposed in obesity and weight-management literature.
However, there is an important clinical caveat:
Protein requirements vary with age, body composition, total energy intake, physical activity, training, medical conditions, kidney function and the magnitude and rate of weight loss.
Recent multidisciplinary guidance on nutrition during GLP-1 therapy discusses several approaches to protein prescription, while acknowledging that the optimal calculation method—particularly in people living with obesity—is not fully settled.[8]
That is why an individualized assessment is more useful than copying a protein target from social media.
A practical strategy is to ask:
Where is the meaningful protein source in this meal?
When appetite is low, waiting until dinner to consume most of the day’s protein may make adequacy difficult.
Instead, protein can be distributed across eating occasions.
Depending on dietary preference and cultural pattern, useful options include:
For someone who becomes full very quickly, eating the protein-containing component earlier in the meal may help prevent vegetables, beverages or other foods from filling the stomach before adequate protein is consumed.
This does not mean vegetables or whole grains are unimportant. It simply recognizes the practical reality of early satiety.
Protein matters.
But protein alone is not a complete muscle-preservation strategy.
Skeletal muscle responds powerfully to mechanical loading. Resistance exercise provides the physiological stimulus telling the body that muscle tissue remains useful and should be maintained.
That is why contemporary GLP-1 nutrition guidance emphasizes combining sufficient protein with structured resistance or strength training rather than relying on protein alone.[8]
Walking remains excellent for cardiovascular health, mobility and overall activity.
But walking and strength training are not physiologically identical.
A comprehensive programme may include appropriately prescribed exercises such as:
Squats or sit-to-stands • rows • presses • hinges • lunges • step-ups • resistance-band movements • machine or free-weight exercises
The exact programme should match the individual’s ability, experience, health conditions and physical limitations.
For someone beginning from a low fitness level, professionally supervised progression may be appropriate.
The quality of weight loss matters alongside the quantity.
Imagine that someone previously consumed three full meals and several snacks.
After starting therapy, that person may manage only two small meals and perhaps one snack.
Their nutritional requirements have not disappeared simply because their appetite has.
This creates what might be called a nutrient-density challenge.
The aim is to obtain meaningful nutrition from a smaller amount of food.
A strong dietary foundation generally includes:
Protein-rich foods + vegetables and fruit + whole grains or other minimally processed carbohydrate sources + legumes + nuts and seeds + unsaturated fats + appropriate calcium-rich foods.
The precise pattern can be Mediterranean, South Asian, vegetarian, pescatarian or culturally adapted in many other ways.
There is no requirement to follow a branded “GLP-1 diet.”
The principle is more important than the label:
When total intake falls, every meal has more nutritional work to do.
Reduced food intake can unintentionally reduce fibre.
At the same time, constipation is a commonly reported gastrointestinal adverse effect with GLP-1–based therapies.[5,9,10]
Vegetables, fruits, legumes, oats, whole grains, nuts and seeds can therefore remain valuable.
But suddenly adding very large quantities of fibre while fluid intake remains inadequate can make gastrointestinal discomfort worse for some people.
Increase fibre gradually when necessary and pair it with appropriate hydration.
If constipation becomes persistent, severe or is associated with significant abdominal symptoms, it should not simply be treated as a DIY nutrition problem. The prescribing clinician should be involved.
People sometimes associate reduced appetite only with food.
In practice, interest in drinking may decline too, and nausea, vomiting or diarrhoea can increase fluid losses.
Regular fluid intake should therefore be intentional.
Water will meet most hydration needs, although individual requirements vary with body size, climate, activity, pregnancy or lactation status, kidney or heart conditions and gastrointestinal losses.
A useful principle is:
Sip consistently rather than trying to compensate with a very large volume at once.
People who have fluid restrictions for medical reasons should follow their clinician’s guidance rather than generic hydration targets.
Gastrointestinal adverse effects are among the most common difficulties associated with GLP-1–based treatment.[3–5,9,10]
Nutrition cannot eliminate every medication side effect, but meal structure can sometimes improve tolerability.
Strategies that may help include:
A previously normal portion may simply be too large once appetite and gastric tolerance change.
Rapid eating can make it easier to cross the new threshold between comfortably satisfied and uncomfortably full.
Finishing a predetermined portion is not necessary when fullness arrives earlier.
High-fat or fried meals may be particularly difficult for some people experiencing nausea, reflux or prolonged fullness.
Yogurt, soups, eggs, smoothies, cottage cheese, tofu or other gentle foods can sometimes be easier to manage than a large solid meal.
Skipping food because appetite is absent can lead to an extremely low intake and make meeting protein and micronutrient needs increasingly difficult.
The objective is not to force large meals.
It is to create small, tolerable, nutritionally useful eating opportunities.
A reduced appetite can create concern about micronutrient deficiencies.
That concern is reasonable—but it does not mean every GLP-1 user automatically needs a long list of supplements.
Potential inadequacies depend on baseline diet, degree of food restriction, duration of therapy, medical history, age and other factors.
Nutrients that may deserve assessment in selected individuals include:
vitamin B12, vitamin D, calcium, iron and other micronutrients, depending on dietary pattern and clinical circumstances.[8]
A multivitamin-mineral supplement may sometimes be useful when dietary intake is substantially reduced, but supplements should complement rather than replace food.
Protein powders can also be useful when chewing or consuming sufficient solid protein becomes difficult.
They are a convenience—not a requirement.
The strongest strategy remains:
Assess → identify the gap → correct the gap.
Not:
Assume → supplement everything.
People taking medications should also discuss supplements and herbal products with an appropriate healthcare professional because “natural” does not automatically mean clinically useful or interaction-free.
One of the more concerning consequences of GLP-1 culture is the idea that eating as little as physically possible means the medication is “working better.”
It does not.
Severe restriction can make it difficult to obtain sufficient protein, essential fats, fibre, vitamins and minerals.
It may also increase fatigue, reduce training capacity and make preservation of lean tissue more difficult.
For some individuals, rapid or substantial weight loss also warrants attention to gallbladder health and other clinical risks.[9,10]
The medication has already altered appetite regulation.
There is rarely a nutritional prize for adding unnecessary starvation on top of that effect.
There is no universally correct GLP-1 meal plan.
But when appetite is limited, a useful meal-building sequence can be:
Eggs, yogurt, fish, tofu, chicken, cottage cheese, paneer, beans, lentils or another appropriate protein.
Vegetables and/or fruit according to tolerance.
Oats, potatoes, rice, whole grains, beans or culturally relevant staple foods.
Nuts, seeds, avocado, olive oil or other unsaturated-fat sources.
Nutrient quality matters more than forcing a conventional plate size.
For example:
Breakfast: Greek yogurt or unsweetened fortified soy yogurt + berries + chia seeds + oats
Lunch: Lentil or chicken bowl + cooked vegetables + a modest portion of rice or another whole grain
Snack: Cottage cheese, yogurt, milk/fortified soy beverage or another protein-rich option with fruit
Dinner: Fish/tofu/paneer + vegetables + potato, beans or whole grains
This is a framework, not a prescription.
Cultural foods can—and should—be incorporated.
Many people using GLP-1 medicines also live with type 2 diabetes.
GLP-1 therapies themselves have glucose-dependent actions that generally carry a relatively low intrinsic risk of hypoglycaemia, but risk can increase when they are combined with certain glucose-lowering medicines, particularly insulin or sulfonylureas.[9,10]
If food intake drops dramatically while diabetes medications remain unchanged, glucose management may need reassessment.
Symptoms or documented episodes of hypoglycaemia should therefore be discussed promptly with the treating clinician.
Medication doses should not be independently altered on the basis of nutrition advice from an article.
Not every gastrointestinal symptom should be dismissed as “normal on GLP-1.”
Persistent vomiting, inability to maintain hydration, severe or persistent abdominal pain, symptoms suggesting gallbladder disease, suspected pancreatitis, severe gastrointestinal symptoms or other significant deterioration require clinical assessment.[9,10]
Likewise, treatment should be reviewed when food intake becomes so limited that nutritional adequacy cannot reasonably be maintained.
Medication dose escalation should be managed by the prescriber—not accelerated simply because someone wants faster weight loss.
And GLP-1 medicines should be obtained through legitimate medical and pharmaceutical channels. WHO has specifically highlighted safety concerns associated with falsified and substandard products as global demand has increased.[1]
GLP-1 treatment is often discussed through a single number:
kilograms lost.
But a clinically meaningful assessment can be broader.
Depending on the individual, useful outcomes may include:
Someone who loses slightly less total weight while maintaining strength, eating adequately and improving metabolic health may have achieved a highly meaningful outcome.
The smallest possible body is not the objective of evidence-based obesity care.
Better health is.
Another mistake is treating these medicines like a short diet challenge:
Take the medicine.<br>Lose the weight.<br>Stop the medicine.<br>Return to “normal.”
Obesity biology is often more complicated.
In the STEP 1 extension, participants who stopped semaglutide after 68 weeks regained a substantial proportion of the weight they had previously lost during the following year, while several cardiometabolic improvements moved back toward baseline.[11]
This does not mean every individual will have the same experience.
It does reinforce an important principle:
WHO’s 2025 guidance similarly frames GLP-1 therapy within comprehensive, long-term obesity care rather than as an isolated pharmaceutical intervention.[1]
Nutrition therefore should not be postponed until the medication stops.
The habits that support adequate protein, fibre, micronutrients, movement, strength and dietary quality need to be developed during treatment.
GLP-1 medicines have changed what is possible in obesity treatment.
They should also change how nutrition professionals think about dietary care.
Traditional weight-loss advice often begins with:
How can we reduce calorie intake?
For someone whose medication has already profoundly reduced appetite, that may no longer be the most important question.
The clinical nutrition priorities become different:
Can this person meet their protein needs?
Are they maintaining strength and function?
Is their diet still supplying sufficient vitamins, minerals and fibre?
Are gastrointestinal symptoms interfering with eating or hydration?
Is the rate of weight loss appropriate for their clinical situation?
Are they developing a dietary pattern they could realistically sustain?
And is weight loss improving health rather than simply making the scale smaller?
This is the distinction between eating less and being well nourished while eating less.
At NIND, GLP-1 nutrition should therefore be approached as a process of nutritional protection during medically supported weight management.
Medication can change appetite.
It cannot automatically build a nutritionally adequate diet.
Medication can facilitate substantial weight loss.
It cannot replace resistance exercise as a stimulus for muscle.
And medication can reduce the biological barriers to weight management.
It does not eliminate the need for individualized, evidence-based and compassionate nutrition care.
The goal is not to make food disappear from obesity treatment. It is to make every smaller eating opportunity count.
1. GLP-1 therapy is not a starvation strategy.<br>Reduced appetite is an expected therapeutic effect; extreme dietary restriction is not the goal.
2. Protect muscle intentionally.<br>Adequate protein combined with appropriately prescribed resistance training is more meaningful than simply chasing the lowest possible calorie intake.
3. There is no universal protein number for every GLP-1 user.<br>Requirements should consider body composition, age, activity, medical conditions, kidney function and the rate of weight loss.
4. Smaller appetite means greater need for nutrient density.<br>Prioritize protein-rich foods, vegetables, fruits, legumes, whole grains, healthy fats and appropriate calcium-rich foods.
5. Manage gastrointestinal symptoms rather than simply eating nothing.<br>Smaller meals, slower eating and individually tolerated foods may help, while significant or persistent symptoms require medical review.
6. Supplements are tools—not substitutes for a diet.<br>Use them to address demonstrated or probable nutritional gaps rather than taking extensive combinations automatically.
7. Think beyond weight.<br>Strength, metabolic health, nutritional status, function and quality of life are important treatment outcomes.
8. Plan for the long term.<br>GLP-1 medicines are increasingly understood within chronic obesity management. Nutrition and lifestyle care should therefore be built alongside pharmacotherapy, not saved for after it.
Dt. Neha Vijh is a Certified Clinical Dietitian, Women’s Health Expert, IVF Nutrition Expert, Internationally Certified PCOS Coach and Internationally Certified Dietary Supplement Practitioner.
As Founder & Director of NIND, her professional work focuses on translating nutrition science into practical clinical frameworks, with particular emphasis on women’s health, metabolic nutrition, PCOS and evidence-informed dietary practice.
The NIND Knowledge Hub is the evidence-focused nutrition education and professional knowledge platform of NIND, created to bridge the gap between nutrition research, clinical practice and understandable health information.
Its Clinical Insights interpret emerging nutrition and health topics through an evidence-informed lens for consumers, students and healthcare professionals.
1. World Health Organization. WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults. Geneva: World Health Organization; 2025.
2. World Health Organization. WHO issues global guideline on the use of GLP-1 medicines in treating obesity. Published December 1, 2025.
3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002. doi:10.1056/NEJMoa2032183.
4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205–216. doi:10.1056/NEJMoa2206038.
5. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740–756. doi:10.1016/j.cmet.2018.03.001.
6. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564. doi:10.1111/dom.14725.
7. Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab. 2025.
8. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025.
9. U.S. Food and Drug Administration. Wegovy (semaglutide) prescribing information. Current prescribing information.
10. U.S. Food and Drug Administration. Zepbound (tirzepatide) prescribing information. Current prescribing information.
11. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564.
This article is intended for educational and professional-information purposes only and does not constitute individualized medical, nutritional or pharmaceutical advice. GLP-1 and GIP/GLP-1 medicines are prescription treatments and should be initiated, adjusted or discontinued only in consultation with an appropriately qualified healthcare professional.
Nutritional requirements and medication safety vary according to diagnosis, age, body composition, kidney and liver function, pregnancy status, concurrent medications and other clinical factors. Individuals experiencing severe or persistent gastrointestinal symptoms, dehydration, significant abdominal pain, suspected hypoglycaemia or other concerning symptoms should seek appropriate medical assessment.
Published by The NIND Knowledge Hub<br>Author: Dt. Neha Vijh, Certified Clinical Dietitian<br>Founder & Director – NIND
Evidence • Nutrition • Clinical Practice • Professional Growth
Certified Clinical Dietitian | Women’s Health & Metabolic Nutrition Expert | Founder & Director, NIND
Secure your spot in this session
Secured by Razorpay